Header Logo

Connection

Judith James to Rituximab

Back to Details
This is a "connection" page, showing publications Judith James has written about Rituximab.
Judith James
Connection Strength
0.238
Rituximab
  1. IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus. Cell Rep Med. 2025 Aug 19; 6(8):102247.
    View in: PubMed
    Score: 0.238
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.